Industrial infrastructure in Eastern and Central Regions
A state-owned special purpose vehicle will begin construction of the two hubs in 2027. According to the 2027 Budget Statement, the Eastern and Central Regions will host these special economic zones. This initiative is part of the US$1 billion Pharmaceutical and Biomanufacturing Compact under the New Economy programme. The hubs will provide industrial infrastructure for local and international drug makers to allow for contract manufacturing, research and development, and the production of medicines and other health products.
| Detail | Specification |
|---|---|
| Total Compact Investment | US$1 billion |
| Construction Start Date | 2027 |
| Target Local Production | 60% to 80% by 2030 |
| Designated Locations | Eastern and Central Regions |
The initiative aims to increase the local production of essential medicines to between 60 and 80 per cent by 2030 while it builds capacity to supply other African markets and strengthens local supply chains through technology transfer. These hubs will support the production of medicines and vaccines, create room for skills development, and help reduce the country’s heavy reliance on imported medicines. By helping manufacturers expand production, the government intends to keep more of the industry’s economic value within the country. This program advances the Accra Reset’s vision of health sovereignty by linking Ghana’s health reforms with investment in local manufacturing.
Economic demand and supply requirements
Dr. Bernice Makafui Brempong, the Presidential Coordinator of the Ghana Pharmaceutical Hub, told the 2026 National Pharmacy Heads’ Retreat in Accra that the zones would anchor changes to the sector. "We are in the golden era of the pharmaceutical industry," Brempong said. She added that President John Dramani Mahama is committed to the agenda. She estimated that Ghana spends about GH¢5 billion a year on pharmaceutical products from India and China. Expanding domestic manufacturing would keep a significant share of that spending in the country, which Brempong said "will create jobs for our people and foreign exchange for the country." This push for production responds to new demand from the Free Primary Healthcare initiative, the Ghana Medical Trust Fund, Mahama Cares, a strengthened National Health Insurance Scheme, and 24-Hour Health Services.
The Ghana Pharmaceutical Hub will organize the market, secure demand, finance capacity, manufacture medicines, and supply Ghana, West Africa, and the wider continent. Dr. Martha Gyansa-Lutterodt, the chairperson for the event, said a reliable pharmaceutical supply system is necessary for the success of government healthcare reforms. She argued that "free care should not mean out of stock" and that patients must consistently get the medicines they need, use them safely, and complete treatment without interruption. This requires a competent pharmaceutical workforce and systems built around reliable, safe and patient-centred care. The effort also protects the jobs and livelihoods of medicine importers, distributors, and their employees. Dr. Brempong noted that the government must reinforce the systems and workforce behind these healthcare initiatives to handle the new demand.


